#IVERMECTIN COVID TRIAL#

The results of another clinical trial conducted by Monash University into the use of ivermectin as an antiviral against COVID-19 are also yet to be published. Researchers from one trial at the University of Oxford told Reuters they did not wish to comment on the results of the Malaysian trial until they were ready to report the outcomes of their own analysis. Several other trials investigating the use of ivermectin as a COVID-19 treatment are ongoing, but the results of a previous randomised clinical trial in Argentina also found no significant effect of ivermectin hospitalisation rates for patients with COVID-19. ‘The generalisability of our findings may be limited by the older study population, although younger and healthier individuals with low risk of severe disease are less likely to benefit from specific COVID-19 treatments,’ the paper reads. The authors also said the older age of the study cohort could limit its relevance. However, the researchers also acknowledged several study limitations, including that the trial’s open-label design could lead to under-reporting of adverse events in the control group, and overestimates of drug effects among the ivermectin group. ‘The notably higher incidence of in the ivermectin group raises concerns about the use of this drug outside of trial settings and without medical supervision,’ the authors wrote. Five of the adverse events were classified as serious, including four among the ivermectin group. There were 13 deaths among the entire cohort, or 2.7% of the entire group.Ī total of 55 adverse events was recorded in 44 patients, with 33 of them among the ivermectin group.

The daily ivermectin doses were set 0.4 mg per kilogram of body weight, the paper states.Īuthors describe standard care as consisting of ‘symptomatic therapy and monitoring for signs of early deterioration’ based on clinical findings, laboratory test results, and chest imaging.

They were then randomised to either receive standard care and a five-day course of ivermectin taken orally over five days, or standard care alone. Likewise, all trial participants had mild-to-moderate disease when they were enrolled, with asymptomatic patients excluded from the trial. Patients were enrolled within a week of the onset of COVID-19 symptoms, and all of them had laboratory-confirmed COVID-19 as well as at least one comorbidity. ‘The study findings do not support the use of ivermectin for patients with COVID-19.’ ‘In this randomised clinical trial of high-risk patients with mild to moderate COVID-19, ivermectin treatment during early illness did not prevent progression to severe disease,’ the paper reads. The researchers conclude that ivermectin use did not provide protection against severe disease among the cohort. There were 43 patients of the 249 (17.3%) in the control group who went on to have severe disease. Of the 241 people in the ivermectin group, 52 (21.6%) went on to develop severe disease. The main outcome measured by the trial was the onset of severe disease, which was defined as the requirement for additional oxygen to keep the patients’ oxygen saturation at 95% or higher. The results of the study appeared in a peer-reviewed article published this month on the Jama Network, an open access medical journal overseen by the American Medical Association.įour hundred and ninety people aged over 50 were recruited to the Malaysia-based trial, which took place across 20 public hospitals and a COVID-19 quarantine facility between 31 May and 25 October last year. The use of ivermectin to treat patients with mild-to-moderate COVID-19 does not prevent the onset of severe disease, the researchers behind a randomised clinical trial have concluded. The use of ivermectin since the pandemic began has proved contentious. The drug’s use on mild-to-moderate COVID-19 patients does not stop disease progression, a newly published clinical trial suggests.

Ivermectin covid